couter

ALTAltimmune, Inc.

Altimmune, Inc. (ALT) develops and commercializes therapies for metabolic and liver diseases, with a focus on pemvidutide, a GLP-1 receptor agonist for non-alcoholic steatohepatitis (NASH). The next catalyst is Nov 12, 2026 — Q4 2022 Earnings Release, which will test the company’s ability to deliver in-line revenue and manage cash burn amid costly Phase 3 trials.

  • Altimmune has a narrow revenue base, with $200,000 in revenue for the nine months ended September 30, 2022.
  • The company has been burning cash, with a TTM free cash flow of -$150.48M and a net margin of -43,482.5%.
  • Altimmune’s debt-to-equity ratio is 0.16x, suggesting limited leverage but heavy reliance on equity financing.
Nov 12, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Thu12Nov
  • Thu17Dec

    The announcement will test the market's reaction to updates on the Pemvidutide drug, particularly its potential progress and regulatory status. This event is crucial for assessing the company's ability to meet expectations and maintain investor confidence.

  • Fri12Feb
  • Thu25Feb

    The strategic partnership update will test the market's reaction to any new collaborations or business developments that could enhance Altimmune's growth prospects and financial position.

  • Wed12May
  • Tue25May

    The participation in investor conferences will test the market's reaction to the company's communication strategy and any updates on its drug development and financial outlook.

  • Fri4Jun

    The participation in upcoming investor events will test the market's reaction to the company's communication strategy and any updates on its drug development and financial outlook.

  • Thu12Aug

Past

  • Tue15Sep

    Actual outcome: Bull · $3.25 at outcome

    ALT's stock rose following the GLP-1 competitor data readout as positive clinical results from key competitors raised investor confidence in the GLP-1 space. The market interpreted the data as supportive of ALT's market share position, driving the price above the bull target.

    Anticipated clinical data readouts from major GLP-1 competitors influencing relative valuation.

  • Thu13Aug

    Actual outcome: Bull · $3.01 at outcome

    Altimmune reported narrower-than-expected Q2 losses and provided positive updates on its pemvidutide trials, including the initiation of the global Phase 3 PERFORMA trial in MASH and progress in AUD studies. The stock rallied on strong guidance and strategic development momentum, despite the EPS beat, as investors focused on the company's cash runway and advancing clinical programs.

    Quarterly earnings report focused on R&D spend trajectory following the Phase 3 trial launch.

  • Thu28May

    The release of Phase 2 top-line results for Pemvidutide will test the market's reaction to the drug's performance, which is critical for assessing its potential and Altimmune's future prospects.

  • Wed27May

    This event will test the market's response to potential data from mid-stage trials of GLP-1 drugs, which could impact Altimmune's valuation and investor perception of its drug pipeline.

  • Wed13May

    Actual outcome: Bear · $2.86 at outcome

    Altimmune reported in-line EPS of -0.18, but the stock fell 5.5% as concerns over cash burn and the lack of a confirmed strategic partner for pemvidutide trials weighed on sentiment. The price dropped below the bear floor, reflecting market skepticism about the company's ability to fund its Phase 3 trials independently.

    Altimmune's Q1 report will likely face intense scrutiny over its cash burn trajectory as the company attempts to independently fund its pemvidutide Phase 3 MASH trials without a confirmed strategic partner.

Scouting Reports